Holen Sie sich die Stockscreener-App
0.0001
33.64%
-0.0602
Paxmedica Inc Aktie (PXMD) Neueste Nachrichten
PaxMedica Renames to Kuvatris, Cancels Shares - TipRanks
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
PaxMedica announces board resignations amid transition By Investing.com - Investing.com Canada
PaxMedica announces board resignations amid transition - Investing.com Australia
PaxMedica Announces Board Chairman Resignation Amid Transition - TipRanks
PaxMedica Holds Important FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data - ACCESS Newswire
PaxMedica, Inc. Announces Board Changes -February 06, 2025 at 04:05 pm EST - Marketscreener.com
Paxmedica, Inc. Announces Resignation of Stephen D. Sheldon as Chief Financial Officer - Marketscreener.com
PaxMedica CFO and COO Stephen D. Sheldon Resigns, Zachary Rome Steps Down from BoardOn January 31, 2025, PaxMedica, Inc. (NASDAQ:PXMD) saw significant changes in its executive leadership and board composition. Stephen D. Sheldon, the chie - Defense World
PaxMedica Announces Gold Sponsorship of The BRAIN Foundation's Synchrony Symposia 2023 - ACCESS Newswire
PaxMedica Announces Resignation of Key Executives - TipRanks
PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions - ACCESS Newswire
Craft Capital Management Announces Pricing of Initial Public Offering for PaxMedica, Inc. - ACCESS Newswire
PaxMedica Secures Immediate Exercise of Warrants - ACCESS Newswire
BioMedNewsBreaks – PaxMedica Inc. (PXMD) Secures Patent Approval in China for Autism Treatment - Financial Content
PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection - Yahoo Finance
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101 - Yahoo Finance
PXMD Stock Price and Chart — OTC:PXMD - TradingView
PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast - Yahoo Finance
As Autism Cases Rise, Biopharma Springs Into Action - BioSpace
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101 - GlobeNewswire
PaxMedica Receives Emergency Request for IV Suramin from - GlobeNewswire
Why Is PaxMedica (PXMD) Stock Up 93% Today? - InvestorPlace
PaxMedica Achieves Key Milestone in the Development of - GlobeNewswire
Paxmedica Inc (PXMD) QuotePress Release - The Globe and Mail
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments - GlobeNewswire
PaxMedica Releases Fireside Chat Video with CEO Howard Weisman - StreetInsider
Penny Stocks To Buy? 5 To Watch Right Now - PennyStocks.com
Why Is PaxMedica (PXMD) Stock Down 40% Today? - InvestorPlace
PaxMedica progresses with PAX-101 for sleeping sickness By Investing.com - Investing.com UK
What's Going On With PaxMedica Stock Today? - Benzinga
Why Is PaxMedica (PXMD) Stock Up 95% Today? - InvestorPlace
PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV) - GlobeNewswire
PaxMedica (NASDAQ: PXMD) to jump 1,700% todaypurely nominal and technical - Dhaka Tribune
PaxMedica Announces 1-for-17 Reverse Stock Split - GlobeNewswire
PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication - GlobeNewswire
PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update - GlobeNewswire
PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC - GlobeNewswire
PaxMedica Comments on Common Stock Volatility - GlobeNewswire
PaxMedica seeks SAHPRA approval to initiate ASD therapy trial - Clinical Trials Arena
PaxMedica Submits Clinical Trial Request in Autism Spectrum Disorder - GlobeNewswire
PaxMedica and PoloMar to investigate emodin in ASD trial - Clinical Trials Arena
PaxMedica Enters Research Collaboration Agreement With - GlobeNewswire
PaxMedica Completes HAT-301 Registrational Trial for PAX-101 - GlobeNewswire
PaxMedica Announces NASDAQ Closing Bell Ringing to Celebrate Initial Public Offering and Autism Awareness Month - Yahoo Finance
5 Short Squeeze Stocks To Watch: Getty Images, PaxMedica, A Mental Health Care Company And More By Benzinga - Investing.com UK
PaxMedica, Inc. Provides Business Update and Reports Fourth Quarter 2022 Financial Results - Yahoo Finance
Best Penny Stocks To Buy? 3 Short Squeeze Stocks To Watch - Penny Stocks
Autistic Disorder Clinical Trial Pipeline Insights Featuring 25+ Companies | DelveInsight - GlobeNewswire
PaxMedica Releases 2022 Shareholder Letter - Yahoo Finance
PaxMedica to Present at the Jan 26th Virtual Investor Summit Microcap Event - Yahoo Finance
Ambrx Biopharma, PaxMedica And 3 More Short Squeeze Stocks That Could Soar This Week - Benzinga
PaxMedica, Inc. Launches Updated Corporate Website at - GlobeNewswire
PaxMedica to Present at the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference - GlobeNewswire
PaxMedica (PXMD) Stock Soared 41% on a $20 Mln Funding Deal - AskTraders.com
PaxMedica, Inc. Enters Into Committed Equity Investment Agreement for up to $20 Million With Lincoln Park Capital - GlobeNewswire
PaxMedica, Inc. Provides Corporate Update After IPO - GlobeNewswire
PXMD News Today | Why did PaxMedica stock go up today? - MarketBeat
PaxMedica (PXMD) Stock Price, News & Analysis - MarketBeat
PaxMedica, Inc. Announces Pricing of Initial Public Offering - Yahoo Finance
SAHPRA grants approval to begin trial of PaxMedica’s long Covid-19 therapy - Clinical Trials Arena
IV suramin may be a promising autism treatment, shows Phase II study - European Pharmaceutical Review
PAX-101 meaningfully improves core symptoms of autism - European Pharmaceutical Review
IPO Launch: PaxMedica Proposes Terms For $15 Million IPO - TheStreet
IPO Preview: PaxMedica Files For $18 Million U.S. IPO - TheStreet
1.86%
1.98%
Kapitalisierung:
|
Volumen (24h):